This section provides essential information on the use of Favipiravir under this EUA for the management of adult patients (aged 18 years and older) with mild to moderate COVID-19, combined with standard supportive care.
Refer to this fact sheet for information on use of Favipiravir under the EUA.
DOSING: The optimal dosing and duration of treatment is unknown.
Favipiravir must be administrated by orally.
The optimal dosing and duration of treatment is unknown.
The suggested dose under this EUA for Favipiravir to treat adults patients with mild to moderate COVID-19 is in accordance with the available clinical trials and current available guideline on the procedure for the treatment of COVID-19, which is: 1600 mg orally twice daily for first day followed by 600 mg orally twice daily on subsequent days until 7 to 14 days, based on clinical consideration by prescriber. The total administration period should not be more than 14 days.
The suggested dose and duration may be updated as data from clinical trials becomes available.
Method of administration: Careful Administration: Favipiravir should be administered with care in Patients with gout or a history of gout, and patients with hyperuricaemia (Blood uric acid level may increase, and symptoms may be aggravated).
Special Populations: Elderly population (>65 years of age): Since the elderly often have reduced physiological functions, Favipiravir should be administered with care to them by monitoring their general conditions.
Pediatrics population (<18 years of age): Favipiravir has not been administered to children.